RT Journal Article
SR Electronic
T1 Expression of Methylthioadenosine Phosphorylase cDNA in<em>p16</em>
<sup>−</sup>, <em>MTAP</em>
<sup>−</sup>Malignant Cells: Restoration of Methylthioadenosine Phosphorylase-Dependent Salvage Pathways and Alterations of Sensitivity to Inhibitors of Purine <em>de novo</em> Synthesis
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 903
OP 911
DO 10.1124/mol.52.5.903
VO 52
IS 5
A1 Chen, Zhi-Hao
A1 Olopade, Olufunmilayo I.
A1 Savarese, Todd M.
YR 1997
UL http://molpharm.aspetjournals.org/content/52/5/903.abstract
AB 5′-Deoxy-5′-methylthioadenosine phosphorylase (MTAP) is involved in the salvage of adenine and methylthio moieties of 5′-deoxy-5′-methylthioadenosine, a byproduct of polyamine synthesis, to adenine nucleotides and methionine, respectively. The gene encoding MTAP, MTAP, is frequently codeleted along with the tumor suppressor gene p16 in malignant cells bearing homozygous deletions in the chromosome 9p21 region.p16 −, MTAP −malignant cells have been shown to be more susceptible to the purinede novo inhibitory actions of antifolates such as methotrexate than are p16 +,MTAP + cells. To understand the underlying mechanism, we reintroduced MTAP activity into twop16 −, MTAP −cell model systems, the MiaPaCa-2 and PANC-1 human pancreatic carcinoma cell lines, by transfection with MTAP cDNA. It was found that transfection with MTAP cDNA (i) restored both the MTAP-dependent adenine and methionine salvage pathways, (ii) decreased the rates of purine de novo synthesis (18–47% lower than the wild-type or sham-transfected counterparts), and (iii) decreased cellular sensitivity to the antipurine-related growth-inhibitory actions of methotrexate and azaserine. These data support the hypothesis that operation of the MTAP-dependent adenine salvage pathway renders MTAP + cells less dependent on de novo purine synthesis and hence less susceptible than MTAP − malignant cells to the growth-inhibitory actions of agents (e.g. antifolates) whose mechanism of action in part involves the de novo purine pathway. These findings provide a theoretical basis for the relatively selective action certain antifolates may have against MTAP-deficient malignancies.